Generation Bio Stock

generationbio.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $125.37MM

Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases.

Register for Details

For more details on financing and valuation for Generation Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Generation Bio.

Register Today


Management Team

Thomas Graney
Chief Financial Officer
Will McCarthy
Chief Business Officer
Jason Rhodes
Chairman & Co-Founder
Mark Angelino Ph.D
Chief Operating Officer & Co-Founder
Robert Kotin Ph.D
Co-Founder & Head of Discovery
Geoffrey McDonough MD
Chief Executive Officer, President & Board Member
Jennifer Elliott Ph.D
Vice President, Head of Legal Affairs and Intellectual Property

Board Members

Donald Nicholson Ph.D
Anthony Quinn Ph.D
Geoffrey McDonough MD
Gustav Christensen
Jeffrey Jonas MD
Catherine Stehman-Breen MD
Jason Rhodes

Other companies like Generation Bio in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Xconomy: Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans
JP Morgan’s annual healthcare conference convenes in San Francisco this week and Generation Bio CEO Geoff McDonough is betting gene therapy will be among
Generation Bio Raises $110M in Series C Financing | FinSMEs
Generation Bio, a Cambridge, MA-based gene therapy company, closed a $110m Series C financing. round led by T. Rowe Price funds and accounts
Generation Bio Welcomes Steven Dowdy, Ph.D., to its Scientific Advisory Board
Generation Bio announced that Steven Dowdy, Ph.D., has joined its Scientific Advisory Board.
Updated on: Oct 2, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.